Overview

Erythropoietin in Acute Myocardial Infarction

Status:
Unknown status
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have shown that EPO has protective effects when organs such as the heart and brain are injured by lack of oxygen due to reduced blood supply. We wish to test the idea that giving a patient, who is having a heart attack, an injection of EPO will reduce the size of the heart attack.
Phase:
Phase 2
Details
Lead Sponsor:
Hammersmith Hospitals NHS Trust
Treatments:
Epoetin Alfa